Related Experiment Video
Updated: Jul 14, 2026
Multiplexed Fluorescent Microarray for Human Salivary Protein Analysis Using Polymer Microspheres and Fiber-optic Bundles
Published on: October 10, 2013
Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study
Alireza Minagar1, Irena Adamashvili, Roger E Kelley
1Department of Neurology, LSU Health Sciences Center, Shreveport, Louisiana, USA. aminag@lsuhsc.edu
Objective:
Potential surrogate markers of disease activity, including response to therapy, are particularly important in a neurological disorder such as multiple sclerosis (MS) which often has a fluctuating course. Based upon previous studies in our laboratory, we hypothesized that measurement of soluble HLA (sHLA) molecules class II in saliva of MS patients can serve as marker of therapeutic response to high dose interferon beta-1a.
Methods:
We measured the expression patterns of sHLA-II in saliva in 17 patients with relapsing/remitting MS and compared the results to clinical course and brain MRI. For comparison purposes we also assayed the saliva sHLA-II levels in 53 normal control subjects. Solid phase ELISA was used for measurement of sHLA-I and sHLA-II concentrations at baseline and after three and six months of treatment with high dose interferon beta-1a (IFN beta-1a).
Results:
The mean saliva sHLA-ll levels in MS patients was significantly higher than normal controls (354 +/- 42 unit/mL vs. 222 +/- 18 unit/mL, t= 8.16, p < 0.003). Comparison of saliva sHLA-II values before and after treatment with IFN beta-1a revealed a consistent increase in mean concentration. The increase in saliva sHLA-II values (354 +/- 42 unit/mL at baseline versus 821 +/- 86 unit/mL at 3 months and 776 +/- 63 unit/mL at 6 months, in unit/mL, p < 0.001 for both comparisons) was associated with a stable clinical course and a decline of the number of contrast-enhancing lesions on brain MRI. Comparison of the volume of T2-weighted lesions and the number of black holes on T1-weighted images did not reveal any significant changes (during pre-treatment versus post-treatment month 6) or any correlations with saliva sHLA-II levels. Saliva sHLA-I levels were not detectable.
Conclusion:
Serial measurement of saliva sHLA-II may serve as a potential marker of therapeutic response to IFN beta-1a. Larger clinical studies involving more RRMS patients over longer periods of time are needed to further test the significance and value of saliva sHLA-II as an accurate marker of therapeutic response to beta-interferons.
